magistrsko delo
Povzetek
Terapije s celicami T, ki izražajo himerne antigenske receptorje (ang. chimeric antigen receptor T cells; CAR-T), predstavljajo učinkovit pristop za zdravljenje določenih malignih obolenj. Zaradi resnih stranskih učinkov, ki se pri teh terapijah pojavljajo, je pomemben razvoj strategij za uravnavanje aktivnosti celic CAR-T. Načrtovali in testirali smo pristop inducibilne inhibicije signaliziranja receptorjev CAR na osnovi kemijsko inducirane dimerizacije (ang. chemically induced dimerization; CID). Kot heterodimerizacijski domeni smo uporabili človeški retinol vezavni protein 4 (ang. human retinol binding protein; hRBP4) in načrtovan hRBP4 vezavni protein RS3, dimerizacijo katerih sproži mala molekula A1120. Ugotovili smo, da slednji ligand do koncentracije 10 µM ni citotoksicen za testirane sesalske celice. S testom z razcepljeno luciferazo nam ni uspelo dokazati delovanja sistema CID. Nato smo načrtovali receptorje CAR z znotrajceličnima ali zunajceličnima domenama hRBP4 in RS3, ki naj bi ob dodatku A1120 dimerizirali in k znotrajcelični signalizacijski domeni receptorja CAR pripeljali inhibitorno domeno fosfataze CD45, kar bi inhibiralo nadaljnje signaliziranje. Za preverjanje inducibilne inhibicije smo celice Jurkat, ki so izražale naše konstrukte, gojili s tumorskimi celicami Raji z izraženim tarčnim antigenom CD19, ob odsotnosti in prisotnosti induktorja ter izmerili koncentracijo človeškega interlevkina-2 v supernatantu. Pri nobenem izmed načrtovanih receptorjev CAR s sistemom CID, ob dodatku A1120, niti pri najvišji uporabljenih koncentracijah, nismo opazili inhibicije signaliziranja preko CAR. Ugotavljamo, da sistem CID na osnovi hRBP4 in RS3 ni primeren za namen inhibicije signaliziranja preko receptorjev CAR z inhibitornimi domenami CD45.
Ključne besede
CAR-T celice;CAR;CRS;CID;uravnavanje signaliziranja;
Podatki
Jezik: |
Slovenski jezik |
Leto izida: |
2023 |
Tipologija: |
2.09 - Magistrsko delo |
Organizacija: |
UL BF - Biotehniška fakulteta |
Založnik: |
[A. Jelenčič] |
UDK: |
606:616-006.6:577.2(043.2) |
COBISS: |
162424067
|
Št. ogledov: |
15 |
Št. prenosov: |
3 |
Ocena: |
0 (0 glasov) |
Metapodatki: |
|
Ostali podatki
Sekundarni jezik: |
Angleški jezik |
Sekundarni naslov: |
Heterodimerization domains of human origin for regulation of CAR-T cell signaling |
Sekundarni povzetek: |
Chimeric antigen receptor T-cell (CAR-T) therapies are an effective treatment for
certain malignancies. Due to the occurrence of serious side effects, the development of
strategies to regulate CAR-T cell activation is crucial. We developed and tested an
approach of inducible inhibition of CAR signaling based on the chemically induced
dimerization (CID) system consisting of the heterodimerization domains human
retinol-binding protein 4 (hRBP4) and modified archaeal protein RS3, which dimerize
upon addition of the inducer A1120. We found the latter not to be excessively
cytotoxic up to the concentration of 10 µM. Split luciferase assay failed to show the
functioning of the CID system. We generated fusion proteins based on intra- and
extracellular hRBP4 and RS3 domains that were supposed to dimerize after the
addition of A1220, bringing the inhibitory domains of the phosphatase CD45 to the
intracellular signaling region of CAR and inhibiting further signaling. To test
inducible inhibition, we cocultivated Jurkat cells expressing our fusion proteins with
Raji cells expressing the target antigen CD19 in the absence or presence of A1120 and
measured the concentration of human interleukin-2 (hIL-2) in the supernatant. We did
not observe inhibition upon the addition of 5 or 10 µM A1120 with the constructs
containing intra- or extracellular heterodimerization domains. We conclude that the
CID system based on hRBP3 and RS3 is not suitable for use in CAR signaling
inhibition with CD45 inhibitory domains. |
Sekundarne ključne besede: |
CAR-T cells;regulation of signaling; |
Vrsta dela (COBISS): |
Magistrsko delo/naloga |
Študijski program: |
0 |
Konec prepovedi (OpenAIRE): |
1970-01-01 |
Komentar na gradivo: |
Univ. v Ljubljani, Biotehniška fak., Študij biotehnologije |
Strani: |
1 spletni vir (1 datoteka PDF (X, 56 str.)) |
ID: |
19849260 |